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Objective: Several randomized controlled trials (RCTs) have shown the superiority of some of these technologies over
balloon angioplasty, but direct comparisons between these treatment options are lacking. The authors conducted a
network meta-analysis of RCTs comparing bare nitinol stents, covered nitinol stents, paclitaxel- or sirolimus-eluting
stents (PES or SES), and paclitaxel-coated balloons (PCB) with plain balloon angioplasty or with each other in the
femoropopliteal artery (PROSPERO registry: CRD42013004845).
Methods: Sixteen RCTs comprising 2532 patients with 4227 person-years of follow-up were analyzed on an intention-to-
treat basis. Bayesian random effects Poisson and binomial models were used for mixed treatment comparisons (Win-
BUGS). Clinical heterogeneity was accounted for by incorporating a meta-regression model on trial-speciﬁc baseline risk.
End points included technical success, vascular restenosis, target lesion revascularization, and major amputations. Pair-
wise odds ratios and rate ratios (ORs and RRs) of absolute treatment effects were calculated, and the probabilities of each
treatment being best are reported. Summary estimates are reported as the posterior median and associated credible in-
tervals (CrIs) that serve the same purpose as conﬁdence intervals in the context of the Bayesian framework. Extensive
sensitivity, meta-regression, and network consistency analyses were performed to evaluate heterogeneity.
Results: Technical success was highest with covered stents (pooled OR, 13.6; 95% CrI, 3.3-31.1, probability best 82%)
followed by uncovered stents (pooled OR, 7.0; 95% CrI, 2.6-129, probability best 18%) when compared with balloon
angioplasty (reference treatment). Vascular restenosis was lowest with PES (RR, 0.43; 95% CrI, 0.16-1.18, probability
best 45%) followed by PCB (RR, 0.43; 95% CrI, 0.26-0.67, probability best 42%). Target lesion revascularization was
lowest with PCB (RR, 0.36; 95% CrI, 0.23-0.55, probability best 56%) followed by PES (RR, 0.42; 95% CrI, 0.16-1.06,
probability best 33%). Major amputations were rare in all treatment and control groups (pooled amputation rate of 0.7
events per 100 person-years).
Conclusions: Immediate technical success is better with the use of covered stents, whereas paclitaxel-eluting stents and
paclitaxel-coated balloons offer the best long-term results in the femoropopliteal artery. (J Vasc Surg 2014;59:1123-33.)the Department of Interventional Radiology, Guy’s and St. Thomas’
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://dx.doi.org/10.1016/j.jvs.2014.01.041The femoropopliteal artery is the most common site
of involvement in patients with peripheral arterial disease1
and an endovascular-ﬁrst strategy is now recommended
for the majority of symptomatic patients.2,3 However, the
femoropopliteal arteries have high rates of restenosis after
endovascular treatment because of their unique anatomy
and biomechanics. Balloon-expandable metal stents are
no longer used in the femoropopliteal segment because
of the risk of external compression and longitudinal axis
deformation under conditions of vessel torsion, ﬂexion,
and extension.4 Several new technologies such as bare
nitinol stents, drug-eluting stents, covered stents, and
drug-coated balloons have emerged to improve long-
term patency outcomes after angioplasty of the femoral
and popliteal arteries.5,6
Several randomized controlled trials (RCTs) have
shown the superiority of some of these technologies over
balloon angioplasty (BA), but direct comparisons between1123
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analysis on the matter has been limited to bare stents
only.5 Network meta-analysis is capable of comparing
different treatments with a common reference treatment.
When more than two treatments are available (eg, treat-
ments A, B, C) an RCT network allows an indirect compar-
ison of any two treatments (eg, direct comparisons of A vs
B and of B vs C imply an indirect comparison of A vs C).
Whereas a simple meta-analysis pools trials with the same
two treatments, network meta-analysis aggregates results
over an RCT network into a single uniﬁed analysis while
fully respecting randomization.7,8 A large-scale compre-
hensive mixed treatment comparison (MTC) network
meta-analysis was performed to provide a qualitative anal-
ysis and quantitative data synthesis of recent evidence
from major RCTs investigating different endovascular
treatment options for the management of arterial occlusive
disease of the femoropopliteal artery.
METHODS
Selection process. This systematic review has been
registered and published in the PROSPERO public data-
base of meta-analyses (CRD42013004845; http://www.
crd.york.ac.uk/PROSPERO). Electronic searches of
PubMed (Medline, 1950 to present), EMBASE (Excerpta
Medical Database, 1980 to present), AMED (Allied and
Complementary Database, 1985 to present), Scopus (1970
to present), the CENTRAL (Cochrane Central Register of
Controlled Trials), archives of regulatory authorities (FDA,
EMA, MHRA), proceedings of international conferences,
and other relevant online material were performed to
identify RCTs that evaluated endovascular treatment op-
tions for femoropopliteal arterial occlusive disease. There
were no restrictions on publication language, date, or sta-
tus. For the purpose of this network meta-analysis, the
search extracted trials comparing primary placement of
bare nitinol stents (BNS), covered nitinol stents (CNS),
paclitaxel-eluting stents (PES), sirolimus-eluting stents
(SES), or paclitaxel-coated balloons (PCB) with BA or with
each other in the femoropopliteal artery (Appendix, online
only). The trial selection process complied with the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses statement.9 The quality of the included
RCTs was evaluated with the Cochrane Collaboration’s
tool for assessing risk of bias10 (Appendix, online only).
Outcome measures. The outcome measures of the
systematic review were deﬁned according to previously
published international guidelines and analyzed strictly on
an intention-to-treat basis.11 For example, in the RESIL-
IENT trial, the initial publication reported the outcomes
on a treatment-received basis.12,13 However, outcomes
were converted and analyzed on the intention-to-treat
principle within the framework of this meta-analysis. For
the ZILVER-PTX trial, all patients assigned to a ZILVER-
PTX were grouped together and data were analyzed on
intention-to-treat after the secondary randomization.14 A
detailed description of data management and extraction of
number of events of all included RCTs is presented in theAppendix (online only). End points included technical
success, vascular restenosis, target lesion revascularization
(TLR), and major amputations. Technical success was
deﬁned as successful recanalization of the target vessel with
no signiﬁcant residual stenosis on completion angiogram
(30-50% threshold, depending on the trial design) and
without any bail-out stenting in the case of BA trials.
Cross-overs to the other treatment arm were considered as
technical failures. Vascular restenosis was evaluated on the
50% threshold by quantitative vascular angiography or
color Doppler ultrasonography (DUS) if angiography was
not available (peak systolic velocity ratio [PSVR] $2.0-2.5,
depending on the trial design). TLR included any repeat
procedures because of signiﬁcant in-lesion restenosis asso-
ciated with recurrent symptoms. Major amputations
included any limb loss that extended above the ankle
(below-knee or above-knee).
Statistical methods. Network meta-analysis combines
only the data summaries for each RCT without any of the
raw data. Quantitative data synthesis of the connected
network of RCTs was performed with Bayesian inference
with the use of Gibbs sampling methods that allow com-
bined direct and indirect MTCs (WinBUGS 1.4.3, MRC
Biostatistics Unit, Cambridge, United Kingdom). Design
and Bayesian modeling of the present network meta-
analysis complied with the guidelines of the National
Institute for Health and Excellence Decision Support Units
(NICEDSU).15-17 For the purposes of this analysis, we ﬁrst
ﬁtted a Bayesian hierarchical random-effects model for
multiple comparisons of different treatment options with
the use of BA as the treatment reference.7 A random-effects
model was chosen to allow for heterogeneity among trials
on the assumption that various treatment effects originated
from a normal distribution. Bayesian inference with Win-
BUGS uses Markov Chain Monte Carlo (MCMC) simu-
lation to calculate the posterior distributions of the
interrogated nodes within the framework of the chosen
model and likelihood function and on the basis of some
prior assumptions. Minimally informative priors for effect
sizes and precisions were used for all calculations of the
present analysis to avoid bias.
Bayesian results are reported as the median and accom-
panying 95% credibility intervals (95% CrIs) of the posterior
distribution. CrIs serve the same purpose as conﬁdence in-
tervals in frequentist statistics. In the case of Bayesian infer-
ence, 95% CrIs that do not cross unity (for relative effects)
or zero (for absolute effects) are considered signiﬁcant and
would be equivalent to a signiﬁcance of a < .05 in case of
frequentist inference. Event counts were analyzed with an
MTC random-effects binomial model for the purpose of
the immediate end point of technical success and pooled
effect estimates were expressed as pairwise odds ratios
(ORs). Vascular restenosis and TLR were recorded as
counts of events per 100 person-years (rates) to account
for the variable follow-up period between RCTs and
analyzed with an MTC random-effects Poisson model to
calculate pairwise rate ratios (RRs) between different treat-
ments. Extensive meta-regression analysis with the
Fig 1. Trial selection process according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses
statement.
Fig 2. Detailed analysis of the risk of bias of each included randomized controlled trials (RCTs) according to the
Cochrane Collaboration Tool.
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riates was also performed. The baseline risk of events
varied widely in the reference treatment arms. Baseline
risk may be a proxy for unmeasured but important
patient-level characteristics that produce signiﬁcant clinical
heterogeneity. This uncertainty was accounted for by
incorporating a meta-regression model on trial-speciﬁc
baseline risk of the control arms, and reported results
are centered on the mean value of covariate baseline risk
as described elsewhere in detail.18,19 To further address
statistical heterogeneity, we calculated and report 95%
prediction intervals that incorporate effect variance be-
tween studies calculated by the random-effects model to
predict a more conservative summary treatment effect of
a future similar trial.19,20The probability of each treatment being the best
(lowest or highest rate of events) was calculated to provide
a more comprehensible measure of treatment efﬁcacy and
plots of cumulative ranking probabilities (rankograms) to
illustrate how each treatment ranks against each other in
terms of being the ﬁrst, second, or third, and so forth,
best treatment option were constructed as proposed else-
where.21 Potential publication bias was assessed by visual
inspection of inverted funnel plot asymmetry. The
Cochran’s Q (c2) and the I2 statistical test were calculated
to test for evidence of statistical heterogeneity. In the case
of MTC network meta-analyses, the risk of network incon-
sistency is greatly reduced if between-trial heterogeneity is
low.22 Consistency of pairwise direct and indirect effect es-
timates generated by the MTC network were evaluated
Fig 3. Mixed treatment comparison (MTC) network of evidence.
The straight lines denote direct head-to-head comparisons and the
dotted lines denote indirect comparisons in which direct compari-
son data are missing. The numbers next to the solid lines refer to
the number of randomized controlled trials (RCTs), with direct
comparisons available for each link.
Fig 4. Condensed network of evidence in the case of technical
success analysis. The straight lines denote direct head-to-head
comparisons and the numbers next to the solid lines refer to the
number of randomized controlled trials (RCTs), with direct
comparisons available for each link.
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An extended description of the statistical methods is pre-
sented in the Appendix (online only) (WinBUGS codes
available on request).
RESULTS
RCT selection and description. In total, 16 RCTs
were found to be eligible, and full-text publications or
other detailed archived records were analyzed5,6,12,14,24-38
(Fig 1). All trials were of generally high quality (Fig 2).
Baseline demographics and procedural variables of the
randomized populations were well matched among the
active and control treatment arms in all 16 trials
(Supplementary Tables I and II, online only). The majority
of enrolled subjects were treated for intermittent claudi-
cation, and only a small percentage of cases had critical
limb ischemia. However, there was signiﬁcant variation
between trials in both the rate of initial chronic total oc-
clusions and the lesion length treated. The shortest lesions
were generally randomized in trials comparing BNS with
BA and the longest in trials comparing CNS with BA,
whereas lesion length was average in other treatment
comparisons (PES, SES, and PCB). Meta-regression tech-
niques were incorporated in our Bayesian modeling to
account for this variation, as outlined in the Online statis-
tical methods in more detail.19 Dual antiplatelet therapy for
at least 1 month (up to 6 months) was recommended after
the procedure in the majority of trials (Appendix, online
only).
Network analysis. Sixteen two-arm RCTs including
2532 patients with 4227 person-years of follow-up were
incorporated into the present MTC Bayesian model. The
mean duration of follow-up was 22 months (range, 9-
48 months). The applied MTC network of evidence isshown in Fig 3. In the case of immediate technical suc-
cess, the network was condensed to a triangle comparing
standard BA (including the control BA and active PCB
study arms) vs uncovered nitinol stents (including the
active BNS, PES, and SES study arms) vs covered nitinol
stents (the active CNS study arms) (Fig 4). For the pur-
poses of vascular restenosis analysis, ﬁndings from vascular
angiography (n ¼ 7 trials) were pooled together with
DUS results (PSVR >2.4; n ¼ 7 trials and PSVR >2.0;
n ¼ 2 trials) for detection of events of signiﬁcant reste-
nosis of the femoropopliteal artery (50% threshold).
Overall, there was no signiﬁcant visual asymmetry of the
respective funnel plots (available on request), and the
Egger test did not produce any signiﬁcant results to
suggest small study effects or publication bias. Results of
quantitative analysis of heterogeneity are provided in the
Appendix (online only).
Technical success. Data on immediate procedural
technical success were reported in the majority of RCTs
(n ¼ 14). Balloon angioplasty was the treatment of refer-
ence, with a calculated median technical success rate of
73.9%. Both uncovered and covered nitinol stents achieved
signiﬁcantly higher success rates, approximately 95% and
98%, respectively, in comparison with BA. Covered stents
were related with the highest probability (82.1%) of being
best, and uncovered stents ranked second, with an 18%
probability of being best (covered stents > uncovered
stents > BA; Supplementary Table III, online only, and
Fig 5). Both uncovered and covered stents exhibited low
numbers needed to treat (NNTs) (approximately 5), with
relatively narrow CrIs. The forest plot of posterior pairwise
ORs is shown in Fig 6. ORs were statistically signiﬁcantly
different in both uncovered (OR, 7.0; 95% CrI, 2.6-129)
and covered stents (OR, 13.6; 95% CrI, 3.3-31.1)
compared with BA, but no signiﬁcant difference was noted
when comparing uncovered with covered stents.
Vascular restenosis. Data on quantitative vascular
angiography or DUS follow-up imaging at various time
points were reported by all RTCs (n ¼ 16). BA was the
reference treatment, with a calculated median rate of
Fig 5. Rankograms of the cumulative ranking probabilities for (A) technical success, (B) vascular restenosis, and (C)
for target lesion revascularization (TLR). On the horizontal axis is the possible rank of each option, based on relative
efﬁcacy (ﬁrst best to last worse). On the vertical axis is the cumulative probability of each treatment per rank (prob-
ability to be the ﬁrst, second, third, etc, best option). The larger the area under the cumulative probability ranking curve
the better the treatment compared with the rest.21
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Compared with BA, all investigated treatments showed
reduced restenosis, but the magnitude of the effect varied.
PCB and PES were the most efﬁcacious (both at 19
events/100 py), CNS had an intermediate effect (27
events/100 py), and BNS and SES were the least efﬁca-
cious (both at approximately 35 events/100 py). PES had
the highest probability (45%) of being the best treatment
(lowest rate of events), followed by PCB, with a 42%
probability (PES > PCB > SES > CNS > BNS > BA;Supplementary Table III, online only, and Fig 5). All
therapies were associated with single-digit NNTs (posterior
medians), with the least uncertainty (narrow CrIs) being
observed with PCB, PES, and CNS. A Forest plot of
posterior rates ratios of events of different pairwise com-
parisons is shown in Fig 7. Compared with BA, PCB (RR,
0.43; 95% CrI, 0.26-0.67) and CNS (RR, 0.60; 95% CrI,
0.36-0.94) had signiﬁcantly fewer events, whereas BNS
(RR, 0.78; 95% CrI, 0.57-1.06) and PES (RR, 0.43; 95%
CrI, 0.16-1.18) were marginally non-signiﬁcantly different
Fig 6. Random-effects Forest plot of pooled estimates of technical success for the condensed network of evidence. The
black lines denote 95% credible intervals (CrIs) and the gray lines denote 95% prediction intervals. The numbers
represent odds ratios (ORs) and 95% CrIs.
Fig 7. Random-effects Forest plot of pooled estimates of vascular restenosis. The black lines denote 95% credible
intervals (CrIs) and the gray lines denote 95% prediction intervals. The numbers represent odds ratios (ORs) and 95%
CrIs. BA, Balloon angioplasty; BNS, bare nitinol stent; CNS, covered nitinol stent; PCB, paclitaxel-coated balloon; PES,
paclitaxel-eluting stent; SES, sirolimus-eluting stent.
JOURNAL OF VASCULAR SURGERY
1128 Katsanos et al April 2014(upper CrI slightly above unity). No signiﬁcant differences
were identiﬁed in the rest of potential pairwise compari-
sons, except that PCB was signiﬁcantly better than BNS
(RR, 0.55; 95% CrI, 0.30-0.97; Fig 7).TLR. Data on TLR events were reported by almost all
RCTs (n ¼ 15). BA served as the reference treatment, with
a calculated median TLR rate of 22 events per 100 py. In
comparison with BA, all other options showed decreased
Fig 8. Random-effects Forest plot of pooled estimates of target lesion revascularization (TLR). The black lines denote
95% credible intervals (CrIs) and the gray lines denote 95% prediction intervals. The numbers represent odds ratios
(ORs) and 95% CrIs. BA, Balloon angioplasty; BNS, bare nitinol stent; CNS, covered nitinol stent; PCB, paclitaxel-
coated balloon; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent.
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PES were the most efﬁcacious (8 events/100 py and 9
events/100 py, respectively), whereas the rest showed a
more modest effect; BNS (16 events/100 py), CNS (16
events/100 py), and SES (14 events/100 py). PCB was
associated with the highest probability (56%) of being the
best treatment (lowest rate of events), followed by PES,
with a 33% probability (PCB > PES > SES > CNS >
BNS > BA; Supplementary Table III, online only, and
Fig 5). Only PES and PCB had single-digit NNTs (pos-
terior medians), but the 95% CrIs were narrow and the
lower interval did not cross zero only in the case of PCB.
The Forest plot of posterior RRs of the various pairwise
comparisons is shown in Fig 8. Compared with BA, RRs
were marginally non-signiﬁcantly different, with the upper
CrI slightly exceeding unity in the case of BNS (RR, 0.77;
95% CrI, 0.57-1.07), CNS (RR, 0.74; 95% CrI, 0.45-
1.18), and PES (RR, 0.42; 95% CrI, 0.16-1.06). PCB was
the only treatment that showed consistently signiﬁcantly
lower RRs against BA (RR, 0.36; 95% CrI, 0.23-0.55),
BNS (RR, 0.47; 95% CrI, 0.27-0.80), and CNS (RR, 0.49;
95% CrI, 0.25-0.94). No signiﬁcant difference was noted
between PCB and different drug-eluting stents (Fig 8).Finally, major amputations were rare in all treatment and
control groups (pooled amputation rate of 0.7 events
per 100 py; 95% CrI, 0.4-1.1 events per 100 py;
Supplementary Table III, online only).
Sensitivity, heterogeneity, and consistency anal-
ysis. When examining all outcome measures, application of
a ﬁxed-effectsmodel produced largely similar results in terms
of treatment effects and overall treatment ranking apart from
some numerical differences of pairwise RRs (Forest plots
available on request).However, random-effectsmodelswere
found to produce a considerably better model ﬁt than ﬁxed-
effects and were therefore preferred in the present MTC
Bayesian meta-analysis. Bayesian random-effects computa-
tions were repeated with the introduction of several other
covariates instead of baseline risk, and results did not deviate
signiﬁcantly. Meta-regression plots of effect summaries
against the baseline risk of events are illustrated in Fig 9.
There were no signiﬁcant discrepancies when comparing
95% CrI with 95% prediction intervals of all pairwise com-
parisons shown in Forest plots of Figs 6 through 8. The
overall network of evidence was highly consistent without
any signiﬁcant differences between direct and indirect
computations, as shown in the Forest plots of Fig 10.
Fig 9. Meta-regression plots of effect summaries against the baseline risk of events for (A) technical success, (B)
vascular restenosis, and (C) for target lesion revascularization (TLR). Outcomes in favor of the active treatment are
denoted with log(OR) >0 in the case of technical success and log(OR) <0 in the case of vascular restenosis and TLR.
Pooled effect summaries in the present meta-analysis were reported on the mean covariate value of plain balloon an-
gioplasty denoted by the dotted vertical lines in all cases.19
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merical analysis of publication bias, trial heterogeneity, and
network consistency are provided in Supplementary
Tables IV and V (online only).
DISCUSSION
To our knowledge, this is the ﬁrst comprehensive
network meta-analysis of different endovascular optionsfor occlusive disease in the femoropopliteal artery
combining the evidence of several RCTs. Network meta-
analysis with Bayesian statistics allows for robust MTC
analysis in the case of multiple treatment options. In addi-
tion, it allows for combined direct and indirect compari-
sons of competing treatments while maintaining the
beneﬁts of randomization. The use of Bayesian modeling
in an in-depth, quantitative analysis was performed that
Fig 10. Forest plot of network consistency analysis for comparisons, with n$ 3 trials. Numbers represent the posterior
means and standard deviations (SDs) of the direct, indirect, and overall mixed treatment comparison (MTC) estimates
of the odds ratios (ORs) and rate ratios (RRs). BA, Balloon angioplasty; BNS, bare nitinol stent; CNS, covered nitinol
stent; PCB, paclitaxel-coated balloon; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent.
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Katsanos et al 1131investigated different strategies with BA as the control
comparator in most cases. The analysis focused on the
end points of immediate technical success, future vascular
restenosis, and revascularization procedures performed for
symptomatic recurrent disease.
Traditionally, stents in the femoropopliteal artery are
reserved for cases of failed or suboptimal BA. Typical indi-
cations for use include post-angioplasty elastic recoil or a
residual stenosis (>30%) or a ﬂow-limiting dissection
with the aim to maximize vessel luminal diameter. Howev-
er, this study shows that both standard (bare or drug-
eluting) and covered nitinol stents achieved signiﬁcantly
higher success rates (95%-98%), whereas bail-out stenting
was necessary in one in four BA procedures. Therefore,
permanent scaffolds in the form of bare or covered nitinol
stents produce appear to achieve signiﬁcantly better imme-
diate recanalization results in the femoropopliteal artery.
This is in line with the fact that stents inherently tackle dis-
sections and provide better radial support. Balloons (bare
or drug-coated) do not leave any permanent scaffolds
behind and thus theoretically may be more safe and more
suitable for the distal femoral and popliteal arteries that
have a considerable amount of ﬂexion and torsion.However, neointimal hyperplasia leading to vascular
restenosis remains problematic for femoropopliteal interven-
tions.2,4Methods to inhibit restenosis include stents covered
with polytetraﬂuoroethylene that act as a barrier against
development of hyperplasia (ie, CNS), drug-eluting stents
(ie, SES or PES), and drug-coated balloons (ie, PCB) that
deliver agents such as sirolimus and paclitaxel to the vessel
wall and inhibit neointimal hyperplasia. In the present
MTC network meta-analysis, a beneﬁt of reduced restenosis
and fewerTLR eventswas observed for BNS,CNS, PES, and
PCB options, whereas BA alone consistently ranked as the
least effective therapy. Both PES and PCB ranked as the
best treatments, but only PCB achieved statistically signiﬁ-
cant differences in pairwise comparisons against BA, BNS,
and CNS. PES showed discernible but borderline non-
signiﬁcant differences against most other treatments. On
the basis of these results, the use of stents signiﬁcantly
improves immediate and long-term results, whereas
paclitaxel-coated stents and balloons appear outperform
other therapeutic strategies in the femoropopliteal artery.
Therefore, this evidence questions the paradigm that BA
with provisional stent placement is the accepted standard
of endovascular care for the femoropopliteal arteries.
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network meta-analyses may be prone to uncertainty and
potential bias, which may compromise the accuracy of
the network of evidence. However, sensitivity and consis-
tency analysis have shown the robustness of the present
network. Second, the duration of dual antiplatelet therapy
was variable between different studies (range, 1-6 months),
but the ideal antiplatelet regimen for infrainguinal proce-
dures remains elusive. Use of statins was scarcely reported.
Meta-regression techniques were used to adjust for base-
line risk variability, and sensitivity analysis was also used
to account for the heterogeneity produced by the different
types of stents examined. Regression against baseline risk
showed stronger treatment effects as observed risk of
events increased (Fig 9). All other examined covariates
were associated with weak regression slopes, and no corre-
lation coefﬁcient proved to be statistically signiﬁcant. The
size of study groups was nonetheless limited to support
in depth subgroup analyses, and meta-regression of a larger
number of covariates and long-term follow-up is missing
(average follow-up <2 years across all studies). Third, there
were differences in stent design and geometry with BNS
studies, in polytetraﬂuoroethylene cover with CNS (with
or without heparin coating), in paclitaxel-coating agents
with PCB, and in drug-elution kinetics with SES and
PES. Furthermore, some of the trials have not been
published in peer-reviewed journals (in whole or their
long-term follow-up), and data extraction was based on
or supplemented by presentations and online archived ma-
terial from international meetings or regulatory authorities.
However, we have chosen to include those because of the
limited number of RCTs available and to counteract any
risk of publication bias. For example, both the INTRA-
COIL study (data available from FDA ﬁles) and the
VIBRANT study (reported online in www.clinicaltrials.
gov) have produced negative results and have not been
published in peer-reviewed journals. Finally, the network
of evidence included RCTs spanned more than a decade,
and therefore improvements over time or changes in gen-
eral medical management were not accounted for.
CONCLUSIONS
Immediate technical success is more likely with the use
of either covered or uncovered stents, whereas paclitaxel-
eluting stents and paclitaxel-coated balloons offer the best
long-term results in occlusive disease of femoropopliteal ar-
tery. Results from the present meta-analysis may be
hypothesis-generating during design of further large-scale
clinical trials. More head-to-head RCTs are necessary, and
cost-utility issues must be addressed to strengthen the evi-
dence on clinical and cost-effectiveness of endovascular
treatment of femoropopliteal disease.
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Search process. Evaluation of the quality of the RCTs
included in the meta-analysis was performed independently
by two authors (K.K., M.K.) by applying the Cochrane
Collaboration’s tool for assessing risk of bias.1 The trial
selection process complied with the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA)
statement.2 Three authors (K.K., S.S., and M.K.) designed
the systematic review and individually selected the trials to
be included and independently extracted all presented data
as outlined in this material in detail. Any disagreements
were resolved by consensus between the investigators.
Each study was evaluated for inclusion in the network
meta-analysis with the following criteria: (1) Only RCTs
were included, (2) different endovascular options were
eligible provided that they investigated the aforementioned
therapies, (3) the target population included patients with
femoropopliteal occlusive disease causing either intermit-
tent claudication (IC) or critical limb ischemia (CLI), (4)
immediate outcomes and clinical and angiographic
follow-up of at least 6 months was available, and selected
end points were reported (see outcome measures below).
Only self-expanding nitinol stents were considered for in-
clusion, and balloon-expandable stents were excluded.
The last literature search for eligible RCTs was per-
formed in January 2013 through the use of various relevant
terms and keywords along with corresponding Medical
Subjects Headings (MeSH) as follows: Cochrane, femoral
artery, popliteal artery, femoropopliteal, vascular restenosis,
angioplasty and stent, randomized controlled trial, balloon
angioplasty, primary nitinol stents, bare nitinol stents,
covered nitinol stents, viabahn-covered stents, drug-
eluting stents, drug-coated stents, sirolimus-eluting stents,
everolimus-eluting stents, paclitaxel-eluting stents, drug-
eluting balloons, drug-coated balloons, paclitaxel-coated
balloons, and paclitaxel-eluting balloons.
Data extraction. Descriptive variables extracted from
each trial included a number of baseline demographics,
procedural parameters, follow-up imaging modality, anti-
platelet therapy, and primary and secondary end points for
each treatment group. Data were extracted from the text,
survival curves, and tables of published manuscripts or from
meeting abstracts and presentations indexed online after
international conferences and symposia were held. In the
case of missing or conﬂicting data, the trial investigators
were contacted. After the PRISMA process, the title and
the abstract of 169 scientiﬁc records were screened for
potential inclusion in this MTC analysis. Of those, 149
citations were characterized as irrelevant or incomplete or
not meeting the predeﬁned inclusion criteria and were
excluded from further analysis. Another four items were
discarded because they were duplicate studies reporting an
interim follow-up.
Cochrane Collaboration’s tool for assessing risk of
bias. This method evaluates seven different methodolog-
ical items of an RCT: (1) random sequence generation,
(2) allocation concealment, (3) blinding of participantsand personnel, (4) blinding of outcome assessment, (5)
incomplete outcome data, (6) selective outcome reporting,
and (7) other sources of bias (eg, reporting of sample size
calculation). Each of the above-mentioned domains was
evaluated as high, low, or unclear risk of bias, and dis-
agreements were resolved by consensus.
Statistical methods. Quantitative data synthesis of the
connected network of RCTs was performed by means of
Bayesian inference with the use of Gibbs sampling methods
that allow combined direct and indirect mixed treatment
comparisons (WinBUGS 1.4.3; MRC Biostatistics Unit,
Cambridge, United Kingdom). In addition, direct frequent-
ist inference methods (Fixed Mantel-Haenszel [M-H] or
random DerSimonian and Laird [D-L] effects, RevMan
software [Review Manager Version 5.1; The Cochrane
Collaboration, Copenhagen, Denmark] and the Statsdirect
statistical package [Version 2.7.9, Statsdirect Ltd, Chesh-
ire, United Kingdom]) were applied as necessary. In the
case of zero cells in 2  2 contingency tables, continuity
correction was applied with addition of 0.5 to each
observed frequency to avoid statistical artifacts.
Design and Bayesian modeling of the present network
meta-analysis complied with the guidelines of the National
Institute for Health and Excellence Decision Support
Units (NICEDSU).3-5 For the purposes of this analysis,
we ﬁrst ﬁtted a Bayesian hierarchical random-effects
model for multiple comparisons of different treatment
options with the use of BA as the treatment reference.6
A random-effects (RE) model was chosen to allow for het-
erogeneity among trials on the assumption that various
treatment effects originated from a normal distribution.
Bayesian inference with WinBUGS uses Markov Chain
Monte Carlo (MCMC) simulation to calculate the posterior
distributions of the interrogated nodes within the framework
of the chosen model and likelihood function and on the
basis of some prior assumptions. Bayesian methods require
speciﬁcation of prior distributions and extensive sensitivity
analysis to check assumptions about the model. Minimally
informative priors for effect sizes and precisions were used
for all calculations of the present analysis to avoid bias.
Summary statistics of relative treatment effects are re-
ported as the median and accompanying 95% credibility in-
tervals (95% CrIs) of the posterior distribution. CrIs serve
the same purpose as conﬁdence intervals in frequentist sta-
tistics. In the case of Bayesian inference, 95% CrIs that do
not cross unity (for relative effects) or zero (for absolute ef-
fects) are considered signiﬁcant and would be equivalent to
a signiﬁcance of a ¼ .05 in the case of frequentist inference.
Absolute treatment effects for each individual treatment
option were then calculated on the natural scale and on
the centered covariate value after an exploratory analysis
of the balloon angioplasty control arms. Event counts
were analyzed with an MTC random-effects binomial
model for the purpose of the immediate end point of tech-
nical success, and pooled effect estimates were expressed as
pairwise odds ratios (ORs). Vascular restenosis and TLR
were recorded as counts of events per 100 person-years
(rates) to account for the variable follow-up period
JOURNAL OF VASCULAR SURGERY
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random-effects Poisson model to calculate pairwise rate ra-
tios (RRs) between different treatments.
Extensive meta-regression analysis with the introduc-
tion of several different baseline variables as covariates
was also performed in search of potential predictors of out-
comes. The observed baseline risk of events varied widely in
the reference treatment arms. Treatment effects may vary
according to patient-level variables or trial-speciﬁc charac-
teristics. Baseline risk is a proxy for unmeasured but impor-
tant patient-level characteristics that produce signiﬁcant
clinical heterogeneity. Naive approaches that adjust the
observed risk of events in the control groups or the average
risk of events in the control and treatment groups are
ﬂawed and may produce seriously misleading results. How-
ever, a Bayesian approach with Gibbs sampling (Win-
BUGS) has been recommended as a more appropriate
method for investigating the relationship between treat-
ment effect and underlying baseline risk across trials in
meta-analyses and adjusting for baseline confounders.7,8
For a detailed description of Bayesian modeling methods
to account for baseline risk in network meta-analysis,
when it is of interest to adjust for baseline imbalances to
reduce both heterogeneity and inconsistency, the reader
may refer to other dedicated technical resources.5,7,8
Hence, in the present study, this uncertainty was
accounted for by incorporating a meta-regression model
on trial-speciﬁc baseline risk of the control arms, and re-
ported results are centered on the mean value of covariate
baseline risk as described elsewhere in detail.8,9 To further
address statistical heterogeneity, we calculated and report
95% prediction intervals that incorporate effect variance be-
tween studies calculated by the RE model to predict the
summary treatment effect of a future similar trial.9,10 Pre-
diction intervals may imply the degree of heterogeneity
across trials and will depend on the between-trial variation
of observed treatment effects.
The probability of each treatment being the best
(lowest or highest rate of events) and the numbers-
needed-to-treat (NNTs; 95% CrIs) were also calculated
to provide more comprehensible measures of treatment ef-
ﬁcacy. We constructed rankograms of cumulative rank
probabilities of how each treatment ranks against each
other in terms of being the ﬁrst, second, third, and so forth,
best treatment option as proposed elsewhere.11 Plot cumu-
lative ranking probabilities (rankograms) offer an intuitive
way to illustrate how each treatment effect compares with
the rest of the examined treatment options.
WinBUGS and MCMC. WinBUGS code was written
and adapted according to recommendations of the
NICEDSU (http://www.nicedsu.org.uk).6 Bayesian
inference with WinBUGS uses Markov Chain Monte Carlo
(MCMC) simulation to calculate the posterior distribu-
tions of the interrogated nodes within the framework of the
chosen model and likelihood function and on the basis of
some prior assumptions. Minimally informative priors for
effect sizes and precisions were used for all calculations of
the present analysis to avoid bias. Three Markov chainswere compiled and run, whereas convergence was
conﬁrmed with the Brooks-Gelman-Rubin diagnostic
tool12 and by inspection of history plots of monitored
nodes. An initial burn-in simulation of 50,000 iterations
was discarded, and inference of ﬁnal summary statistics was
based on further simulation of an additional 100,000
iterations.
Heterogeneity, consistency, and sensitivity ana-
lyses. The validity of a network meta-analysis depends on
the distribution of effect modiﬁers (covariates) not only
between studies with a particular comparison (ie, hetero-
geneity in the case of standard pairwise meta-analysis) but
also between different sets of comparisons (ie, inconsis-
tency between direct and indirect study estimates).13 The
straightforward Cochran’s Q (c2) and the I2 statistical test
were calculated to test for statistical evidence of heteroge-
neity between RCTs with the same control and active arms.
Brieﬂy, I2 values <25% indicate low, 25% to 50% moderate,
and >50% high heterogeneity.14 Funnel plots are plots of
the trials’ effect estimates against respective sample sizes
and in the presence of publication or other bias they may
appear to be skewed and asymmetrical.15 In the case of
MTC network meta-analyses, the risk of network incon-
sistency is greatly reduced if between-trial heterogeneity is
low.16 Consistency of pairwise direct and indirect effect
estimates generated by the MTC network were evaluated
with back-calculation by means of the Bucher method.16,17
The random- vs ﬁxed-effects model were examined in
the sensitivity analysis. Random-effects models were
initially used to account for between-trial heterogeneity
in calculating the pooled effect estimates. Bayesian compu-
tations were then repeated with a ﬁxed-effects model to ac-
count for the small number of studies included in some of
the pairwise comparisons of the present MTC. Goodness of
model ﬁt was compared with the posterior mean of the to-
tal residual deviance and the Deviance Information Crite-
rion (DIC) criterion.6 For a good model ﬁt, the residual
deviance must be close to the total number of study arms
analysed, and the model with the lowest DIC is preferred.
The level of statistical signiﬁcance was set at a ¼ .05 for fre-
quentist inference, whereas results associated with 95% CrI
that do not cross unity (for relative effects) or zero (for ab-
solute effects) were considered signiﬁcant in the case of
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Supplementary Table I (online only). Design and characteristics of randomized controlled trials (RCTs) included in
the mixed treatment comparison (MTC) analysis
RCT Registration Comparisons Year Subjects Follow-up, months
INTRACOIL18 n/a BNS vs BA 2001 266 9
ABSOLUTE19,20 NCT00281060 BNS vs BA 2007 104 24
FAST21 n/a BNS vs BA 2007 244 12
ASTRON22 NCT00715416 BNS vs BA 2009 73 12
RESILIENT23-25 NCT00673985 BNS vs BA 2010 206 36
SUPER26 NCT00232843 BNS vs BA 2012 150 12
VIABAHN27 n/a CNS vs BA 2008 197 12
VIBRANT28 NCT00228384 CNS vs BNS 2012 148 36
VIASTAR29-31 ISRCTN48164244 CNS vs BNS 2013 141 12
SIROCCO32-34 NCT00232869 SES vs BNS 2006 93 48
ZILVER-PTX35-37 NCT00120406 PES vs BA 2012 479 36
THUNDER38 NCT00156624 PCB vs BA 2008 102 24
FEMPAC39 NCT00472472 PCB vs BA 2008 87 24
PACIFIER40 NCT01083030 PCB vs BA 2012 91 12
DEBELLUM41 n/a PCB vs BA 2012 50 12
LEVANT 142 NCT00930813 PCB vs BA 2012 101 24
ITT, Intention-to-treat.
For the RESILIENT trial, the initial publication reported the outcomes on a treatment-received basis. However, outcomes were analyzed on the ITT principle
within the framework of this meta-analysis. For the ZILVER-PTX trial, all patients assigned to a ZILVER-PTX were grouped together and data were analyzed
on ITT after the secondary randomization. For the SIROCCO trial, pooled data of the SIROCCO I and II sub-studies were analyzed with the use of QVA
available at 6 months and Duplex follow-up up to 48 months. For the THUNDER trial (three-arm trial), the arm of paclitaxel dissolved in the contrast
medium was excluded from the present network of evidence. For the DEBELLUM trial, only subjects with femoropopliteal lesions were analyzed. For the
LEVANT-1 trial, cases with balloon deployment malfunction (n ¼ 8) were excluded from further analysis. In the latter study randomization between plain BA
and PCB was performed after provisional stent placement in a quarter of the cases (26/101). Some of the trials have not been published yet in peer-reviewed
journals either in whole (INTRACOIL, VIBRANT, VIASTAR, and LEVANT-1) or their long-term follow-up (SIROCCO and ZILVER-PTX). Data
extraction was based on or supplemented by presentations and online archived material from international meetings (VIASTAR, LEVANT-1, SIROCCO, and
ZILVER-PTX) or regulatory authorities (INTRACOIL and VIBRANT).
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Supplementary Table II (online only). Baseline variables of randomized controlled trials (RCTs) included in the
network meta-analysis
Trial
INTRACOIL ABSOLUTE FAST ASTRON RESILIENT SUPER VIABAHN
Active Control Active Control Active Control Active Control Active Control Active Control Active Control
Study arms n ¼ 135 n ¼ 131 n ¼ 51 n ¼ 53 n ¼ 123 n ¼ 121 n ¼ 34 n ¼ 39 n ¼ 134 n ¼ 72 n ¼ 74 n ¼ 76 n ¼ 97 n ¼ 100
Age, years 67 6 11 68 6 10 65 6 10 68 6 10 67 6 9 66 6 10 69 6 9 69 6 10 68 6 10 66 6 9 66 6 9 70 6 9 67 6 10 67 6 10
Male sex 67% 63% 59% 47% 63% 75% 74% 64% 71% 67% 78% 86% 70% 82%
Smoking 82% 80% 53% 36% 68% 73% 35% 44% 72% 83% 24% 26% 51% 46%
Hypertension n/a n/a 92% 87% 83% 83% 82% 80% 84% 94% 66% 67% 68% 65%
Hyperlipidemia n/a n/a 92% 87% 60% 61% 91% 92% 80% 76% n/a n/a 59% 60%
Diabetes 38% 37% 43% 32% 36% 31% 29% 31% 38% 39% 31% 38% 34% 37%
Renal
insufﬁciency
n/a n/a n/a n/a 15% 6% n/a n/a n/a n/a 15% 8% 10% 6%
Claudication n/a n/a 88% 87% 97% 96% 91% 97% 100% 100% 85% 79% 88% 91%
Critical leg
ischemia
n/a n/a 12% 13% 3% 4% 9% 3% n/a n/a 15% 21% 12% 9%
Lesions treated n ¼ 177 n ¼ 175 n ¼ 51 n ¼ 53 n ¼ 123 n ¼ 121 n ¼ 34 n ¼ 39 n ¼ 134 n ¼ 72 n ¼ 74 n ¼ 76 n ¼ 97 n ¼ 100
Occlusions
(CTOs)
23% 17% 37% 32% 37% 25% 38% 39% n/a n/a 96% 91% 20% 30%
Lesion length
(cm)
3.5 6
3.0
3.3 6
3.0
10.1 6
7.5
9.2 6
6.4
4.5 6
2.8
4.5 6
2.8
8.2 6
6.7
6.5 6
4.6
7.1 6
4.4
6.4 6
4.1
12.3 6
5.4
11.7 6
5.2
7.0 6
4.0
7.0 6
4.0
Recommended
antiplatelet
therapy
Aspirin and
ticlopidine
for 1 month
Aspirin þ
clopidogrel
for 3 months
Aspirin þ
clopidogrel
for 1 month
Aspirin þ
clopidogrel
for 3 months
Aspirin þ
clopidogrel
for 3 months
Aspirin þ
clopidogrel
for 1 month
(or LMWH)
Aspirin
(or occasionally
ticlopidine)
Trial
VIBRANT VIASTAR SIROCCO ZILVER-PTX THUNDER FEMPAC PACIFIER
Active Control Active Control Active Control Active Control Active Control Active Control Active Control
Study arms n ¼ 72 n ¼ 76 n ¼ 72 n ¼ 69 n ¼ 47 n ¼ 46 n ¼ 238 n ¼ 241 n ¼ 48 n ¼ 54 n ¼ 45 n ¼ 42 n ¼ 44 n ¼ 47
Age, years 69 63 68 69 66 6 9 66 6 11 68 6 10 68 6 11 69 6 8 68 6 9 67 70 71 6 7 71 6 9
Male sex 63% 64% 67% 75% 66% 78% 66% 64% 65% 63% 60% 60% 59% 64%
Smoking n/a n/a 69% 70% 47% 30% 86% 84% 23% 22% 47% 36% 49% 60%
Hypertension n/a n/a 83% 84% 68% 70% 89% 82% 79% 83% 78% 81% 66% 66%
Hyperlipidemia n/a n/a 68% 68% 64% 63% 76% 70% 69% 63% 58% 59% 50% 47%
Diabetes n/a n/a 35% 36% 43% 35% 49% 42% 50% 46% 40% 55% 43% 28%
Renal
insufﬁciency
n/a n/a n/a n/a n/a n/a 10% 11% n/a n/a n/a n/a n/a n/a
Claudication n/a n/a 86% 91% n/a n/a 90% 91% n/a n/a 96% 93% 95% 96%
Critical leg
ischemia
n/a n/a 14% 19% n/a n/a 10% 9% n/a n/a 4% 7% 5% 4%
Lesions
treated (n)
n ¼ 72 n ¼ 76 n ¼ 72 n ¼ 69 n ¼ 47 n ¼ 46 n ¼ 247 n ¼ 251 n ¼ 86 n ¼ 86 n ¼ 100 n ¼ 101 n ¼ 86 n ¼ 47
Occlusions
(CTOs)
n/a n/a 79% 70% 69% 57% 30% 25% 27% 26% 13% 19% 23% 38%
Lesion
length (cm)
n/a n/a 17.3 18.9 8.5 6
4.4
8.1 6
5.2
5.4 6
4.1
5.3 6
4.0
7.5 6
6.2
4.4 6
6.7
4.0 4.7 7.0 6
5.3
6.6 6
5.5
Recommended
antiplatelet
therapy
n/a Aspirin þ
clopidogrel
for 6 months
Aspirin þ
clopidogrel/
ticlopidine
for 1 month
Aspirin þ
clopidogrel
for 2 months
Aspirin þ
clopidogrel
for 1 month
Aspirin þ
clopidogrel
long-term
Aspirin þ
clopidogrel
for >2
months
DEBELLUM LEVANT 1
Trial Active Control Active Control
Study arms n ¼ 25 n ¼ 25 n ¼ 49 n ¼ 52
Age, years 66 6 6 67 6 6 n/a n/a
Male sex 76% 72% n/a n/a
Smoking 68% 56% n/a n/a
Hypertension 76% 60% 96% 87%
Hyperlipidemia 48% 68% 59% 69%
Diabetes 52% 36% 45% 50%
Renal insufﬁciency n/a n/a n/a n/a
Claudication 64% 60% 94% 93%
Critical leg ischemia 36% 40% 6% 7%
Lesions treated n ¼ 44 n ¼ 48 n ¼ 49 n ¼ 52
Occlusions (CTOs) 21% 22% 41% 42%
Lesion length (mm) 7.6 6 0.6 7.8 6 0.7 8.1 6 3.7 8.0 6 3.8
Recommended
antiplatelet therapy
Aspirin þ
clopidogrel
for 1 month
n/a
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Supplementary Table III (online only). Outcome measures with 95% credible interval (CrI) and probabilities of each
one being best
Median ratea (95% CrI) Probability best, % NNT (95% CrI)
Technical success
Balloon angioplasty 73.9 (52.1-88.0) 0.03 Control
Uncovered stents 95.4 (85.5-99.1) 17.9 4.7 (2.6-10.4)
Covered stents 97.5 (85.1-99.8) 82.1 4.4 (2.3-10.3)
Vascular restenosis
BA 44.9 (14.2-141.4) 0.0 Control
BNS 34.8 (10.6-114.0) 0.04 9.8 ([33.1]-77.7)
CNS 26.8 (7.7-92.0) 5.0 5.8 (1.3-28.9)
PES 19.4 (4.2-88.1) 44.5 4.0 ([8.9]-24.7)
SES 35.9 (7.2-178.4) 8.0 3.7 ([66.5]-72.6)
PCB 19.1 (5.5-65.4) 42.3 4.0 (1.2-13.9)
TLR
BA 21.5 (9.4-49.3) 0.0 Control
BNS 16.8 (6.9-40.4) 0.02 20.1 ([87.0]-142.2)
CNS 15.9 (6.1-41.2) 0.4 15.9 ([134.9]-196.0)
PES 9.1 (2.6-31.2) 32.7 8.2 ([7.3]-42.5)
SES 14.3 (3.5-59.5) 11.2 8.6 ([94.3]-108.8)
PCB 7.8 (3.0-19.7) 55.5 7.4 (3.1-17.9)
Major amputationsb
BA 1.2 (0.4-2.3) n/a Control
BNS 0.5 (0.1-1.1) n/a >1000 ([90.9]-90.9)
CNS 0.4 (0.01-1.2) n/a 15.9 ([10.3]-9.8)
PES 0.0 (0.0-1.9) n/a n/a
SES 0.0 (0.0-4.3) n/a n/a
PCB 1.1 (0.2-2.6) n/a 500 ([45.5]-58.8)
BA, Balloon angioplasty; BNS, bare nitinol stent; CNS, covered nitinol stent; CrI, credibility interval; ITT, intention-to-treat; NNT, number needed to treat;
PCB, paclitaxel-coated balloon; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; TLR, target lesion revascularization.
All end points were analyzed on an ITT principle as described in the Appendix (online only).
aOutcomes expressed as median (95% CrIs) of the posterior distribution of event rates per 100 person-years of follow-up, except of technical success expressed
as the median percentage (%) of enrolled subjects. Negative NNT values indicate a number needed to harm because of a negative treatment beneﬁt.
bThe numbers of events of major amputations were too low in control and active treatment groups (zero cells in a lot of groups), and the Bayesian approach
failed to produce any meaningful results (MCMC chains did not converge). Results refer to event rates per 100 person-years of follow-up as calculated by
means of a standard DerSimonian and Laird random-effects model.
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Supplementary Table IV (online only). Between-trial heterogeneity and network consistency analysis
Comparisons
Publication
bias Heterogeneity MTC Direct Indirect Inconsistency
PActive Control Trials Egger P I2 (%) P Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Technical success
Balloon angioplasty Nitinol stents 7 0.49 .84 93.9 <.001 9.9 (25.1) 14.4 (95.6) 9.6 (26.0) 1.5 (99.1) .99
Vascular restenosis
BA BNS 6 7.94 .08 55.2 .04 0.78 (0.12) 0.84 (0.44) 0.77 (0.12) 1.08 (0.46) .86
BA PCB 5 2.42 .11 0 .71 0.44 (0.11) 0.44 (0.22) 0.44 (0.13) 1.0 (0.25) 1.00
TLR
BA BNS 5 2.44 .17 0 .89 0.79 (0.13) 0.80 (1.0) 0.79 (1.0) 1.0 (1.0) .98
BA PCB 5 3.12 .22 0 .49 0.37 (0.08) 0.41 (0.44) 0.37 (0.08) 1.1 (0.4) .81
Major amputations
Comparisons Publication bias Heterogeneity
MTC Direct Indirect InconsistencyActive Control Trials Egger P I2 (%) P
BA BNS 6 0.08 .92 0 .89 n/a n/a n/a n/a
BA PCB 5 0.05 .97 0 .70 n/a n/a n/a n/a
BA, Balloon angioplasty; BNS, bare nitinol stent; MTC, mixed treatment comparison; PCB, paclitaxel-coated balloon; OR, odds ratio; RR, rate ratio; SD,
standard deviation; TLR, target lesion revascularization.
Heterogeneity and inconsistency statistics reported for comparisons with n $ 3 trials. Posterior means and SDs of the MTC, and the direct analysis estimate of
the ORs and RRs were computed from the Bayesian model. Inconsistency was computed with back-calculation by subtraction of the indirect from the direct
estimate with the Bucher method. In the case of major amputations, the numbers of events were too low, with several zero cells in both control and active
treatment groups, and therefore the Bayesian approach was numerically unstable and failed to produce any meaningful results (MCMC chains did not
converge). Hence, MTC analyses were not feasible, and only direct comparisons with a standard DerSimonian and Laird random-effects model are presented.
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Supplementary Table V (online only). Meta-
regression analysis of network covariates
Covariate Correlation coefﬁcient 95% CrI
Technical success
Smoking 2.46 [12.4]-4.82
Diabetes 0.24 [46.8]-34.4
Lesion length 0.22 [0.26]-0.81
Chronic occlusion 0.01 [9.69]-9.84
Bail-out/cross-over n/a n/a
Average follow-up 0.78 [0.60]-1.95
Publication year 0.19 [0.15]-0.50
Baseline risk 1.17 [2.70]-0.53
Vascular restenosis
Smoking 0.004 [1.50]-1.43
Diabetes 2.96 [4.21]-10.6
Lesion length 0.01 [0.12]-0.10
Chronic occlusion 0.14 [1.13]-1.50
Bail-out/Cross-over 2.24 [8.50]-1.73
Average follow-up 0.19 [0.53]-0.18
Publication year 0.04 [0.12]-0.05
Baseline risk 0.30 [1.06]-0.46
TLR
Smoking 0.47 [1.00]-1.96
Diabetes 2.43 [5.78]-11.9
Lesion length 0.02 [0.12]-0.09
Chronic occlusion 0.34 [1.99]-1.25
Bail-out/Cross-over 0.63 [4.13]-2.93
Average follow-up 0.04 [0.37]-0.29
Publication year 0.01 [0.09]-0.07
Baseline risk 0.31 [1.26]-0.72
BA, Balloon angioplasty; CrI, credibility interval; RCT, randomized
controlled trial; TLR, target lesion revascularization.
This table shows the results of the Bayesian random-effects meta-regression
modeling of the effect of certain covariates on treatment outcomes.
Regression slopes (correlation coefﬁcients) with respective 95% CrIs were
calculated. For the evaluation of the effect of cross-over/bail-out, use of the
comparator device only RCTs randomized against BA (n ¼ 8) were
included in the meta-regression analysis. All examined covariates were
associated with weak regression slopes, and no correlation coefﬁcient proved
to be statistically signiﬁcant. In the case of technical success, a positive
regression slope indicates better outcomes with the active treatment,
whereas a negative slope indicates worse outcomes as the covariate effect
increases. On the other hand, in the case of vascular restenosis and TLR, a
negative regression slope would indicate better outcomes with the active
treatment, whereas a positive slope relates to worse outcomes as the co-
variate effect increases. Bayesian meta-regression could not be performed for
major amputations because the model was numerically unstable. Results are
considered statistically signiﬁcant if the CrIs do not cross zero. Weak cor-
relation coefﬁcients with wide CrIs were noted in all cases. Baseline risk in
the control reference group may be a proxy for unmeasured but important
patient-level characteristics that produce signiﬁcant heterogeneity. There-
fore, the correlation coefﬁcients of baseline risk were included in the present
random-effects Bayesian models to adjust for and reduce clinical hetero-
geneity while calculating absolute and relative treatment effects.8
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